Polycythemia Vera
Polycythemia Vera
Polycythemia Vera (PV) is a rare type of bone marrow cancer that leads to an overproduction of red blood cells. This condition can cause various complications, including increased risk of blood clots, stroke, and heart problems. Regular bloodletting through phlebotomy is often the recommended treatment for PV.
Show Medications for Polycythemia Vera
18/05/2026
Updated: 12/06/2026
Polycythemia Vera
Polycythemia vera (PV) is a rare blood disorder characterized by the overproduction of red blood cells, white blood cells, and platelets in the bone marrow. This condition can lead to an increased risk of blood clots, stroke, and other complications.
Symptoms
The symptoms of polycythemia vera may vary from person to person, but common signs include:
- Pallor: pale skin due to the increased red blood cell count
- Headache: severe headaches caused by increased blood viscosity
- Dizziness: lightheadedness resulting from decreased oxygen delivery to tissues
- Fatigue: excessive tiredness due to the increased red blood cell count
Standard Diagnostic Tests
To diagnose polycythemia vera, your doctor may perform the following tests:
- Complete Blood Count (CBC): a blood test that measures red and white blood cells
- Erythropoietin level: a blood test that measures erythropoietin levels, which can help determine the cause of the increased red blood cell production
- Bone marrow biopsy: a biopsy of bone marrow tissue to examine the bone marrow's cellular structure and function
Treatment Options
The primary goal of treatment for polycythemia vera is to reduce the red blood cell count and prevent complications. Treatment options include:
- Phlebotomy: regular bloodletting to reduce the red blood cell count
- Hydroxyurea: a chemotherapy drug that slows down red blood cell production
- Interferon-alpha: an immunomodulatory therapy that reduces white blood cell count
- Radiation therapy: treatment of bone marrow with ionizing radiation (not typically used as a first-line treatment)
Risk Factors
Polycythemia vera can affect anyone, but certain risk factors increase the likelihood of developing the condition. These include:
- Age > 60 years: increased risk with advancing age
- Family history of polycythemia vera: genetic predisposition
- Previous radiation exposure: increased risk due to ionizing radiation
Treatment of Polycythemia Vera
Gold Standard Treatment:
The gold standard treatment for polycythemia vera is regular bloodletting, also known as phlebotomy.
This procedure involves the removal of a certain amount of blood from the patient to reduce the red blood cell count and alleviate symptoms such as pallor, headache, dizziness, and fatigue.
Alternatives to Phlebotomy:
- Hydroxyurea: This is a chemotherapy drug that works by slowing down the production of red blood cells in the bone marrow. It is often used as an alternative to phlebotomy, especially for patients who are at high risk of developing complications from frequent bloodletting.
- Interferon-alpha: This immunomodulatory therapy works by reducing the production of white blood cells and has been shown to be effective in reducing the red blood cell count in some patients with polycythemia vera.
- Radiation Therapy: In some cases, radiation therapy may be used to treat polycythemia vera. This involves using ionizing radiation to destroy the bone marrow cells that produce excess red blood cells.
Causes and Risk Factors of Polycythemia Vera
Introduction
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by the excessive production of red blood cells, white blood cells, and platelets. Understanding the causes and risk factors of PV is essential for early diagnosis and effective management.Risk Factors
The following are established risk factors associated with an increased likelihood of developing polycythemia vera:- Age > 60 years: The risk of developing PV increases with advancing age, suggesting a potential link between aging and the development of this condition.
- Family history of polycythemia vera: A genetic predisposition to PV has been identified, indicating that individuals with a family history of the disease may be at higher risk.
- Previous radiation exposure: Ionizing radiation has been implicated in the development of PV, suggesting that individuals who have received previous radiation therapy may be at increased risk.